Education
About Us
Working with TipRanks
Follow Us
Giant Biogene Holding Co. Ltd. (HK:2367)
:2367
RESEARCH TOOLSreports
Total Valuation
Giant Biogene Holding Co. Ltd. has a market cap or net worth of HK$61.76B. The enterprise value is HK$50.80B.
Market CapHK$61.76B
Enterprise ValueHK$50.80B
Share Statistics
Giant Biogene Holding Co. Ltd. has 1,070,904,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,070,904,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Giant Biogene Holding Co. Ltd.’s return on equity (ROE) is 0.29 and return on invested capital (ROIC) is 26.87%.
Return on Equity (ROE)0.29
Return on Assets (ROA)0.26
Return on Invested Capital (ROIC)26.87%
Return on Capital Employed (ROCE)0.32
Revenue Per Employee3.15M
Profits Per Employee1.40M
Employee Count1,758
Asset Turnover0.69
Inventory Turnover3.19
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio25.6
PS Ratio0.00
PB Ratio7.29
Price to Fair Value6.60
Price to FCF72.39
Price to Operating Cash Flow56.19
PEG Ratio1.45
Income Statement
In the last 12 months, Giant Biogene Holding Co. Ltd. had revenue of 5.54B and earned 2.06B in profits. Earnings per share was 2.10.
Revenue5.54B
Gross Profit4.55B
Operating Income2.31B
Pretax Income2.46B
Net Income2.06B
EBITDA2.31B
Earnings Per Share (EPS)2.10
Cash Flow
In the last 12 months, operating cash flow was 922.79M and capital expenditures -165.42M, giving a free cash flow of 757.38M billion.
Operating Cash Flow922.79M
Free Cash Flow757.38M
Free Cash Flow per Share0.71
Dividends & Yields
Giant Biogene Holding Co. Ltd. pays an annual dividend of HK$0.658, resulting in a dividend yield of 1.13%
Dividend Per ShareHK$0.658
Dividend Yield1.13%
Payout Ratio29.80%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.02
52-Week Price Change50.67%
50-Day Moving Average62.57
200-Day Moving Average58.85
Relative Strength Index (RSI)55.99
Average Volume (3m)15.35M
Important Dates
Giant Biogene Holding Co. Ltd. upcoming earnings date is Sep 1, 2025, TBA (Confirmed).
Last Earnings DateMar 26, 2025
Next Earnings DateSep 1, 2025
Ex-Dividend DateJun 17, 2025
Financial Position
Giant Biogene Holding Co. Ltd. as a current ratio of 7.66, with Debt / Equity ratio of 0.09%
Current Ratio7.66
Quick Ratio7.29
Debt to Market Cap0.00
Net Debt to EBITDA-1.74
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Giant Biogene Holding Co. Ltd. has paid 396.03M in taxes.
Income Tax396.03M
Effective Tax Rate0.16
Enterprise Valuation
Giant Biogene Holding Co. Ltd. EV to EBITDA ratio is 18.57, with an EV/FCF ratio of 0.00.
EV to Sales7.74
EV to EBITDA18.57
EV to Free Cash Flow0.00
EV to Operating Cash Flow0.00
Balance Sheet
Giant Biogene Holding Co. Ltd. has HK$5.86B in cash and marketable securities with ¥6.71M in debt, giving a net cash position of -HK$5.85B billion.
Cash & Marketable SecuritiesHK$5.86B
Total Debt¥6.71M
Net Cash-HK$5.85B
Net Cash Per Share-HK$5.46
Tangible Book Value Per ShareHK$7.11
Margins
Gross margin is 82.09%, with operating margin of 41.68%, and net profit margin of 37.23%.
Gross Margin82.09%
Operating Margin41.68%
Pretax Margin44.37%
Net Profit Margin37.23%
EBITDA Margin41.70%
EBIT Margin41.13%
Analyst Forecast
The average price target for Giant Biogene Holding Co. Ltd. is HK$75.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$75.20
Price Target Upside28.77% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast54.44%
EPS Growth Forecast35.90%